Companies Dominating the Mitochondrial-Based Therapeutics Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Amgen Inc.
- Takeda Pharmaceuticals
- NeuroVive Pharmaceutical AB
- Reata Pharmaceuticals
- Entogene AG
- Intercept Pharmaceutics
- Stealth Biotherapeutics
- Ixchel Pharma
Browse Key Market Insights with Data Illustration:
In the News
- Stealth BioTherapeutics Inc., a clinical stage biotechnology company focused on the discovery, development and commercialization of novel treatments for diseases caused by mitochondrial dysfunction, announced in September 2023 that it had achieved its target to recruit patients with primary myopathy into the NuPOWER study.
- a collaborative agreement was signed by Primera Therapeutics, the inaugural launch from the cell and gene therapy accelerator Mayflower BioVentures, with Cellectis. The two companies shall cooperate to develop methods for gene editing of mutations in mitochondrial DNA, which can be used as an in vivo therapy against mitochondria disease.
